What is it about?
Evaluation of single 4.5 mg fixed-dose rasburicase in patients with tumor lysis syndrome.
Featured Image
Why is it important?
Provides an alternative dosing regimen with lower cost compared to FDA-approved dosing
Read the Original
This page is a summary of: Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome, Journal of Oncology Pharmacy Practice, April 2016, SAGE Publications,
DOI: 10.1177/1078155216644975.
You can read the full text:
Contributors
The following have contributed to this page